Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

Abstract Background While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients’ quality of life. This study aimed to develop a treatment for inflammatory ulcers as on...

Full description

Bibliographic Details
Main Authors: Kazumi Sano, Kazuhiko Nakadate, Kazuhiko Hanada
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
Minocycline application
Improvement skin disorder
Afatinib
EGFR
NSCLC
Online Access:http://link.springer.com/article/10.1186/s12885-020-06797-2

Internet

http://link.springer.com/article/10.1186/s12885-020-06797-2

Similar Items